Carbaglu

CARBAGLU- carglumic acid tablet, for suspension
Recordati Rare Diseases

Carbaglu bottle label — 60 TabletsCarbaglu carton label — 60 TabletsCarbaglu bottle label — 5 TabletsCarbaglu carton label — 5 TabletsFigure 2

1. INDICATIONS AND USAGE

1.1 Acute and Chronic Hyperammonemia due to N‑acetylglutamate Synthase (NAGS) Deficiency

CARBAGLU is indicated in pediatric and adult patients as:

  • Adjunctive therapy to standard of care for the treatment of acute hyperammonemia due to NAGS deficiency.
  • Maintenance therapy for the treatment of chronic hyperammonemia due to NAGS deficiency.

1.2 Acute Hyperammonemia due to Propionic Acidemia (PA) or Methylmalonic Acidemia (MMA)

CARBAGLU is indicated in pediatric and adult patients as adjunctive therapy to standard of care for the treatment of acute hyperammonemia due to PA or MMA.

2. DOSAGE AND ADMINISTRATION

2.1 Recommended Dosage for Acute or Chronic Hyperammonemia due to NAGS Deficiency

Treatment Initiation
Initiate CARBAGLU treatment as soon as the diagnosis of NAGS deficiency is suspected, which may be as soon as at birth, and managed by a physician and medical team experienced in metabolic disorders.

Dosage for Acute Hyperammonemia due to NAGS Deficiency

  • The recommended daily dosage of CARBAGLU in pediatric and adult patients for acute hyperammonemia due to NAGS deficiency is 100 mg/kg to 250 mg/kg.
  • Divide the daily dosage into 2 to 4 doses and round to the nearest 100 mg (i.e., half of a CARBAGLU tablet).
  • During acute hyperammonemic episodes, administer CARBAGLU with other ammonia lowering therapies, such as alternate pathway medications, hemodialysis, and protein restriction.

Dosage for Chronic Hyperammonemia due to NAGS Deficiency

  • The recommended daily dosage of CARBAGLU in pediatric and adult patients for chronic hyperammonemia due to NAGS deficiency is 10 mg/kg to 100 mg/kg.
  • Divide the daily dosage into 2 to 4 doses and round to the nearest 100 mg (i.e., half of a CARBAGLU tablet).
  • During maintenance therapy, the concomitant use of other ammonia lowering therapies and protein restriction may be needed based on plasma ammonia levels.

Therapeutic Monitoring
Closely monitor plasma ammonia levels. Titrate the CARBAGLU dosage to maintain the plasma ammonia level within the normal range for the patient’s age, taking into consideration their clinical condition (e.g., nutritional requirements, protein intake, growth parameters, etc.).

Adjust the recommended dosage in patients with moderate or severe renal impairment [see Dosage and Administration (2.3)].

2.2 Recommended Dosage for Acute Hyperammonemia due to PA or MMA

Treatment Initiation
Initiate CARBAGLU for the treatment of acute hyperammonemia in patients with a suspected or confirmed diagnosis of PA or MMA.

Dosage for Acute Hyperammonemia due to PA or MMA

  • The recommended daily dosage of CARBAGLU in pediatric and adult patients with acute hyperammonemia due to PA or MMA is:
    • 150 mg/kg/day for patients less than or equal to 15 kg
    • 3.3 g/m2 /day for patients greater than 15 kg
  • Divide the daily dosage into 2 equal doses and round up to the nearest 50 mg (i.e., one-quarter of a CARBAGLU tablet). Administer doses 12 hours apart.
  • Continue CARBAGLU treatment until the patient’s ammonia level is less than 50 micromol/L and for a maximum duration of 7 days.
  • During acute hyperammonemic episodes, administer CARBAGLU with other ammonia lowering therapies, such as intravenous glucose, insulin, L-carnitine, protein restriction, and dialysis.

Adjust the recommended dosage in patients with moderate or severe renal impairment [see Dosage and Administration (2.3)].

2.3 Dosage Adjustment in Patients with Renal Impairment

No dosage adjustment is warranted in patients with mild renal impairment (eGFR 60-89 mL/min/1.73 m2). The recommended dosage of CARBAGLU in patients with moderate or severe renal impairment is shown below.

Moderate Renal Impairment (eGFR 30-59 mL/min/1.73 m2) Severe Renal Impairment (eGFR ≤29 mL/min/1.73 m2)
Acute Hyperammonemia due to NAGS Deficiency 50 mg/kg/day to 125 mg/kg/day divided into 2 to 4 doses and rounded to the nearest 50 mg (i.e., one-quarter of a CARBAGLU tablet) 15 mg/kg/day to 60 mg/kg/day divided into 2 to 4 doses and rounded to the nearest 50 mg (i.e., one-quarter of a CARBAGLU tablet)
Chronic Hyperammonemia due to NAGS Deficiency 5 mg/kg/day to 50 mg/kg/day divided into 2 to 4 doses and rounded to the nearest 50 mg (i.e., one-quarter of a CARBAGLU tablet) 2 mg/kg/day to 25 mg/kg/day divided into 2 to 4 doses and rounded to the nearest 50 mg (i.e., one-quarter of a CARBAGLU tablet)
Acute Hyperammonemia due to PA or MMA
  • 75 mg/kg/day for patients weighing ≤ 15 kg
  • 1.7 g/m2 /day for patients weighting > 15 kg

Divide daily dosage into 2 equal doses and round up to the nearest 50 mg (i.e., one-quarter of a CARBAGLU tablet); administer each dose 12 hours apart.

  • 25 mg/kg/day for patients weighing ≤ 15 kg
  • 0.55 g/m2 /day for patients weighting > 15 kg

Divide daily dosage into 2 equal doses and round up to the nearest 50 mg (i.e., one-quarter of a CARBAGLU tablet); administer each dose 12 hours apart.

2.4 Preparation and Administration

Overview

  • Disperse CARBAGLU tablets in water. Do not swallow whole or crushed.
  • CARBAGLU tablets do not dissolve completely in water, and undissolved particles of the tablet may remain in the mixing container.
  • Take CARBAGLU immediately before meals or feedings.
  • The CARBAGLU suspension has a slightly acidic taste.
  • For all preparations, use in foods or liquids other than water has not been studied and is not recommended.

Oral Administration
For oral administration, administer CARBAGLU as follows:

  • Add a minimum of 2.5 mL of water into a small cup for each CARBAGLU tablet or each ½ or ¼ CARBAGLU tablet needed for the prescribed dose.
  • Add the CARBAGLU tablets to the water in the cup.
  • Carefully stir the tablet and water mixture.
  • Swallow the mixture immediately. Pieces of the tablet may remain in the cup.
  • Rinse the cup with additional water and swallow the mixture immediately. Repeat as needed until no pieces of the tablet are left in the cup.

Use of an Oral Syringe for Oral Administration
For administration via an oral syringe, administer CARBAGLU as follows:

  • Add a minimum of 2.5 mL of water into a small cup for each CARBAGLU tablet or each ½ or ¼ CARBAGLU tablet needed for the prescribed dose.
  • Add the CARBAGLU tablets to the water in the cup.
  • Carefully stir the tablet and water mixture.
  • Draw up the mixture in an oral syringe and administer immediately. Pieces of the tablet may remain in the oral syringe.
  • Refill the oral syringe with a minimum volume of water (1 mL to 2 mL) and administer immediately.
  • Flush the oral syringe again, as needed, until no pieces of the tablet are left in the syringe.

Use of Nasogastric Tube (NG Tube) or Gastrostomy Tube (G-Tube) for Feeding Tube Administration

For patients who have a NG tube or G-tube in place, administer CARBAGLU as follows:

  • Add a minimum of 2.5 mL of water into a small cup for each CARBAGLU tablet or each ½ or ¼ CARBAGLU tablet needed for the prescribed dose.
  • Add the CARBAGLU tablets to the water in the cup.
  • Carefully stir the tablet and water mixture.
  • Draw up the mixture into a catheter-tip syringe.
  • Administer the mixture immediately through the NG tube or G-tube. Pieces of the tablet may remain in the catheter-tip syringe or the feeding tube.
  • Flush immediately with 1 to 2 mL of additional water to clear the NG tube or G-tube.
  • Flush the NG tube or G-tube again, as needed, until no pieces of the tablet are left in the syringe or the feeding tube.

All MedLibrary.org resources are included in as near-original form as possible, meaning that the information from the original provider has been rendered here with only typographical or stylistic modifications and not with any substantive alterations of content, meaning or intent.

This site is provided for educational and informational purposes only, in accordance with our Terms of Use, and is not intended as a substitute for the advice of a medical doctor, nurse, nurse practitioner or other qualified health professional.

Privacy Policy | Copyright © 2022. All Rights Reserved.